RHÖN-KLINIKUM AG continues to report an increase in consolidated revenues and profit. In the first nine months of financial year 2024, revenues were up by EUR 82.1 million to reach EUR 1,171.1 million (9M 2023: EUR 1,089.0 million). Consolidated profit improved by 27.7% to EUR 30.4 million (9M 2023: EUR 23.8 million). At EUR 75.1 million, EBITDA was 2.3% above the level in prior year (9M 2023: EUR 73.4 million). From January to September 2023 a total of 688,787 patients were treated on an inpatient and outpatient basis in the hospitals and medical care centres, 3.6% more compared with the same period of the previous year (9M 2023: 664,594). 

“We are taking various strategic measures enabling us to achieve a stable performance in this challenging market environment and are prepared for the hospital reform. In this regard, we are focusing on our strengths such as the specialisation of our facilities, the high level of treatment quality as well as the close collaboration within the Group’s network. Moreover, we are reinvesting our earnings in new staff and the infrastructure of our facilities to ensure our processes are effective and efficient”, said Prof. Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG. 

Outlook for 2024 confirmed 

For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of EUR 1.6 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between EUR 110 million and EUR 120 million is expected.

The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024. 

The Quarterly Statement for Q3 2024 is published on the Internet.

Contact:

RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com